Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 1 Author(s): Daisuke Okamura , Akira Matsuda , Maho Ishikawa , Tomoya Maeda , Ken Tanae , Mika Kohri , Naoki Takahashi , Nobutaka Kawai , Norio Asou , Masami Bessho Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75mg/m2/daily subcutaneously for 7days every 28days. Hematologic improvements were observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of azacitidine was confirmed in our MDS-F patient.
Source: Leukemia Research Reports - Category: Hematology Source Type: research